{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:43:45Z","timestamp":1794264225813,"version":"4.9.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,7]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Drug development for chronic myelomonocytic leukemia (CMML) has failed to parallel the recent success observed in related myeloid neoplasms. To address these shortcomings, the US Food and Drug Administration (FDA) held a \u201cMini-symposium on CMML: Current State of the Art and Trial Design\u201d in September 2023. This symposium brought together a panel of key FDA regulators and academic experts in CMML drug development to discuss challenges and provide perspectives on future drug development for this disease. The panel explored unique challenges that underlie the lack of therapeutic advances in CMML to date and discussed relevant topics such as clinical trial design, study end points, and key regulatory considerations. This article summarizes the key points of discussion from this symposium to facilitate advancements in the field.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024025648","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T16:28:34Z","timestamp":1730996914000},"page":"1987-1992","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-4151","authenticated-orcid":false,"given":"Anthony M.","family":"Hunter","sequence":"first","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-6262","authenticated-orcid":false,"given":"Raphael","family":"Itzykson","sequence":"additional","affiliation":[{"name":"3Universit\u00e9 Paris Cit\u00e9, G\u00e9nomes, Biologie Cellulaire et Th\u00e9rapeutique U944, INSERM, Centre National de la Recherche Scientifique, Paris, France"},{"name":"4D\u00e9partement H\u00e9matologie et Immunologie, H\u00f4pital Saint-Louis, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"5Hematology and Medical Oncology, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8099-7802","authenticated-orcid":false,"given":"Chatchada","family":"Karanes","sequence":"additional","affiliation":[{"name":"6Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Li","sequence":"additional","affiliation":[{"name":"6Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8362-1977","authenticated-orcid":false,"given":"R. Angelo","family":"de Claro","sequence":"additional","affiliation":[{"name":"6Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly J.","family":"Norsworthy","sequence":"additional","affiliation":[{"name":"6Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Theoret","sequence":"additional","affiliation":[{"name":"6Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD"},{"name":"7Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Pulte","sequence":"additional","affiliation":[{"name":"6Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[{"name":"8Hematologic Malignancies. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2024110716282740000_bib1","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.3390\/ijms22042008","article-title":"Therapeutic advances in oncology","volume":"22","author":"Liu","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2024110716282740000_bib2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th\u00a0edition of the World Health Organization\u00a0classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2024110716282740000_bib3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2024110716282740000_bib4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"15","key":"2024110716282740000_bib5","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","article-title":"Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group","volume":"29","author":"L\u00fcbbert","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024110716282740000_bib6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study","volume":"136","author":"Garcia-Manero","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2024110716282740000_bib7","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","article-title":"Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study","volume":"11","author":"Garcia-Manero","year":"2024","journal-title":"Lancet Haematol"},{"issue":"14","key":"2024110716282740000_bib8","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/blood-2011-05-352039","article-title":"Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial","volume":"118","author":"Braun","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2024110716282740000_bib9","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/leu.2014.85","article-title":"A\u00a0multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia","volume":"28","author":"Drummond","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"2024110716282740000_bib10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/leu.2017.186","article-title":"A\u00a0phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia","volume":"32","author":"Santini","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"2024110716282740000_bib11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.leukres.2013.01.004","article-title":"Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine","volume":"37","author":"Ad\u00e8s","year":"2013","journal-title":"Leuk Res"},{"key":"2024110716282740000_bib12","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ebiom.2018.04.018","article-title":"Prognostic role of gene mutations in chronic myelomonocytic leukemia patients treated with hypomethylating agents","volume":"31","author":"Duchmann","year":"2018","journal-title":"EBioMedicine"},{"issue":"10","key":"2024110716282740000_bib13","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.22.00437","article-title":"Decitabine versus hydroxyurea for advanced proliferative chronic myelomonocytic leukemia: results of a randomized phase III trial within the EMSCO network","volume":"41","author":"Itzykson","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024110716282740000_bib14","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480","article-title":"A\u00a0randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Fran\u00e7ais des My\u00e9lodysplasies and European CMML Group","volume":"88","author":"Wattel","year":"1996","journal-title":"Blood"},{"issue":"12","key":"2024110716282740000_bib15","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood.2021015173","article-title":"Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis","volume":"140","author":"Robin","year":"2022","journal-title":"Blood"},{"issue":"22","key":"2024110716282740000_bib16","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.1158\/1078-0432.CCR-21-0935","article-title":"Integrated human and murine clinical study establishes clinical efficacy of ruxolitinib in chronic myelomonocytic leukemia","volume":"27","author":"Hunter","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2024110716282740000_bib17","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/blood.2019004352","article-title":"Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia","volume":"136","author":"Patnaik","year":"2020","journal-title":"Blood"},{"issue":"suppl 5","key":"2024110716282740000_bib18","first-page":"S773","article-title":"Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN)","volume":"32","author":"Patnaik","year":"2021","journal-title":"Annals of Oncology"},{"issue":"suppl 1","key":"2024110716282740000_bib19","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2021-147827","article-title":"Tagraxofusp (SL-401) in patients with chronic myelomonocytic leukemia (CMML): updated results of an ongoing phase 1\/2 trial","volume":"138","author":"Patnaik","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2024110716282740000_bib20","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"issue":"3991","key":"2024110716282740000_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.2.3991.1","article-title":"Chronic monocytic leukemia","volume":"2","author":"Smith","year":"1937","journal-title":"Br Med J"},{"issue":"1","key":"2024110716282740000_bib22","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","article-title":"RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis","volume":"12","author":"Carr","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"2024110716282740000_bib23","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1097\/HS9.0000000000000150","article-title":"Diagnosis and treatment of chronic myelomonocytic leukemias in adults: recommendations from the European Hematology Association and the European LeukemiaNet","volume":"2","author":"Itzykson","year":"2018","journal-title":"Hemasphere"},{"issue":"3","key":"2024110716282740000_bib24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11899-021-00613-9","article-title":"Genomic landscape and risk stratification in chronic myelomonocytic leukemia","volume":"16","author":"Hunter","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"2024110716282740000_bib25","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1038\/bcj.2015.53","article-title":"An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies","volume":"5","author":"Padron","year":"2015","journal-title":"Blood Cancer J"},{"issue":"10","key":"2024110716282740000_bib26","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2024110716282740000_bib27","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"issue":"19","key":"2024110716282740000_bib28","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"2024110716282740000_bib29","volume-title":"Pemigatinib (pemazyre). Package insert","year":"2023"},{"issue":"7983","key":"2024110716282740000_bib30","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/d41586-023-03135-x","article-title":"US science agencies on track to hit 25-year funding low","volume":"622","author":"Tollefson","year":"2023","journal-title":"Nature"},{"issue":"9","key":"2024110716282740000_bib31","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1038\/s41375-021-01152-1","article-title":"Genomic landscape of MDS\/CMML associated with systemic inflammatory and autoimmune disease","volume":"35","author":"Zhao","year":"2021","journal-title":"Leukemia"},{"issue":"18","key":"2024110716282740000_bib32","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood.2023023593","article-title":"IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation","volume":"143","author":"Hong","year":"2024","journal-title":"Blood"},{"issue":"23","key":"2024110716282740000_bib33","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1016\/j.cell.2022.10.007","article-title":"Macrophages in health and disease","volume":"185","author":"Park","year":"2022","journal-title":"Cell"},{"key":"2024110716282740000_bib34","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research\n          . Adaptive designs for clinical trials of drugs and biologics guidance for industry. 2019. Accessed 31 July 2024. https:\/\/www.fda.gov\/media\/78495\/download."},{"key":"2024110716282740000_bib35","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research\n          . Optimizing the dosage of human prescription drugs and biological products for the treatment of oncologic diseases guidance for industry. 2023. Accessed 31 July 2024. https:\/\/www.fda.gov\/media\/164555\/download."},{"issue":"17","key":"2024110716282740000_bib36","first-page":"2047","article-title":"Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"key":"2024110716282740000_bib37","doi-asserted-by":"crossref","first-page":"106640","DOI":"10.1016\/j.leukres.2021.106640","article-title":"Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy","volume":"109","author":"Hunter","year":"2021","journal-title":"Leuk Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/19\/1987\/2312108\/blood_bld-2024-025648-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/19\/1987\/2312108\/blood_bld-2024-025648-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T16:28:42Z","timestamp":1730996922000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/19\/1987\/517937\/Perspectives-on-drug-development-in-chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":37,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,11,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025648","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]}}}